Otis W. Brawley - Jun 16, 2021 Form 3 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Director
Signature
/s/ Heather D. Turner, as Attorney-in-fact
Stock symbol
LYEL
Transactions as of
Jun 16, 2021
Transactions value $
$0
Form type
3
Date filed
6/16/2021, 07:14 PM
Next filing
Jun 17, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LYEL Option (right to buy) Jun 16, 2021 Common Stock 400K $12.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in equal monthly installments over the thirty-six months following April 9, 2021. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.